# Clinical trial results:
# A Proof of Concept Study to Determine the Minimum Effective Dose and to Assess the Efficacy and Safety of Subcutaneous Injections of FPFS-1169 in Parkinson's Disease Patients

## Summary

| | |
|---|---|
| EudraCT number | 2006-000361-11 |
| Trial protocol | GB |
| Global end of trial date | 30 March 2007 |

### Results information

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 21 July 2022 |
| First version publication date | 21 July 2022 |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | RD 639/24201 |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | Fujimoto Pharmaceutical Corp |
| Sponsor organisation address | 1-3-40 Nishiotsuka Matsubara, Osaka, Japan, 580-0011 |
| Public contact | Dr Lan wuTann, Simbec-Orion Clinical Pharmacology, +44 1443690977, lan.tann@simbecorion.com |
| Scientific contact | Dr Lan wuTann, Simbec-Orion Clinical Pharmacology, +44 1443690977, lan.tann@simbecorion.com |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 31 July 2007 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 30 March 2007 |
| Global end of trial reached? | Yes |
| Global end of trial date | 30 March 2007 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the trial was:
- To determine the minimum effective dose (MED) and corresponding plasma concentrations of subcutaneous injections of FPFS-1169 in Parkinson’s disease patients.

The secondary objectives of the trial were:
- To evaluate the acute effects of subcutaneous injection of FPFS-1169 on the severity of parkinsonian signs in patients with mild to moderately advanced Parkinson’s disease.

- To monitor subject safety by means of frequent clinical evaluations and laboratory tests.

Protection of trial subjects:

The study was conducted in accordance with the Declaration of Helsinki (South Africa 1996) and the ABPI Guidelines for Medical Experiments on Non-Patient Human Volunteers - 1988, amended May 1990.), the Guidelines of the International Conference on Harmonisation (ICH) on Good Clinical Practice (GCP) (CPMP/ICH/135/95), as well as the requirements of the European Union Data Protection Directive 95/46/EC, and other applicable regulatory requirements.

Background therapy:

As part of the study, all patients received a standard dose of levodopa/carbidopa on study Day 1 (study period 1).

Evidence for comparator:

N/A - no comparator products were evaluated in this study.

| | |
|---|---|
| Actual start date of recruitment | 21 September 2006 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | United Kingdom: 10 |
| Worldwide total number of subjects | 10 |
| EEA total number of subjects | 0 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |

| | |
|---|---|
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 4 |
| From 65 to 84 years | 6 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

Study recruitment was undertaken in the United Kingdom. The recruitment process began in September 2006 and concluded in February 2007 with 18 patients screening in order to enrol 10 eligible patients.

### Pre-assignment

Screening details:

Patients were screened to the inclusion/exclusion criteria of the protocol. The following assessments were performed: Informed consent, Medical History including current conditions, Physical Exam, Demographics, Height, Weight & BMI, ECG, Vital Signs, Safety Laboratory Testing/Urinalysis & other specific testing related to Parkinson's Disease.

### Period 1

| | |
|---|---|
| Period 1 title | Overall Trial Period (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Blinding implementation details:

N/A - the study was open label.

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | No |
| **Arm title** | Arm 1 - 3 mg FPFS-1169 |

Arm description:

This was the lowest dose level evaluated in the study. 2 participants were administered 3.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | FPFS-1169 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Dosing frequency was one occasion across 5 study periods (Day 1, Day 8, Day 15, Day 22 & Day 29). Dose levels were adjusted per study period based on assessment of previous dose level administered.

| | |
|---|---|
| **Arm title** | Arm 2 - 4.5 mg FPFS-1169 |

Arm description:

This was the second dose level evaluated in the study. 2 participants were administered 4.5 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | FPFS-1169 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Dosing frequency was one occasion across 5 study periods (Day 1, Day 8, Day 15, Day 22 & Day 29). Dose levels were adjusted per study period based on assessment of previous dose level administered.

| | |
|---|---|
| **Arm title** | Arm 3 - 6.0 mg FPFS-1169 |

Arm description:

This was the third dose level evaluated in the study. 5 participants were administered 6.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | FPFS-1169 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Dosing frequency was one occasion across 5 study periods (Day 1, Day 8, Day 15, Day 22 & Day 29). Dose levels were adjusted per study period based on assessment of previous dose level administered.

| | |
|---|---|
| **Arm title** | Arm 4 - 7.5 mg FPFS-1169 |

Arm description:

This was the fourth dose level evaluated in the study. 2 participants were administered 7.5 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | FPFS-1169 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Dosing frequency was one occasion across 5 study periods (Day 1, Day 8, Day 15, Day 22 & Day 29). Dose levels were adjusted per study period based on assessment of previous dose level administered.

| | |
|---|---|
| **Arm title** | Arm 5 - 9.0 mg FPFS-1169 |

Arm description:

This was the fifth dose level evaluated in the study. 3 participants were administered 9.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | FPFS-1169 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Dosing frequency was one occasion across 5 study periods (Day 1, Day 8, Day 15, Day 22 & Day 29). Dose levels were adjusted per study period based on assessment of previous dose level administered.

| | |
|---|---|
| **Arm title** | Arm 6 - 12.0 mg FPFS-1169 |

Arm description:

This was the sixth dose level evaluated in the study. 8 participants were administered 12.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | FPFS-1169 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Dosing frequency was one occasion across 5 study periods (Day 1, Day 8, Day 15, Day 22 & Day 29). Dose levels were adjusted per study period based on assessment of previous dose level administered.

| | |
|---|---|
| **Arm title** | Arm 7- 15.0 mg FPFS-1169 |

Arm description:

This was the seventh dose level evaluated in the study. 2 participants were administered 15.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | FPFS-1169 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Dosing frequency was one occasion across 5 study periods (Day 1, Day 8, Day 15, Day 22 & Day 29). Dose levels were adjusted per study period based on assessment of previous dose level administered.

| | |
|---|---|
| **Arm title** | Arm 8 - 18.0 mg FPFS-1169 |

Arm description:

This was the eighth dose level evaluated in the study. 3 participants were administered 18.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | FPFS-1169 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Dosing frequency was one occasion across 5 study periods (Day 1, Day 8, Day 15, Day 22 & Day 29). Dose levels were adjusted per study period based on assessment of previous dose level administered.

| | |
|---|---|
| **Arm title** | Arm 9 - 21.0 mg FPFS-1169 |

Arm description:

This was the ninth dose level evaluated in the study. 1 participant was administered 21.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | FPFS-1169 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Dosing frequency was one occasion across 5 study periods (Day 1, Day 8, Day 15, Day 22 & Day 29). Dose levels were adjusted per study period based on assessment of previous dose level administered.

| | |
|---|---|
| **Arm title** | Arm 10 - 24.0 mg FPFS-1169 |

Arm description:

This was the highest dose level evaluated in the study. 1 participant was administered 24.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | FPFS-1169 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Dosing frequency was one occasion across 5 study periods (Day 1, Day 8, Day 15, Day 22 & Day 29). Dose levels were adjusted per study period based on assessment of previous dose level administered.

| Number of subjects in period 1 | Arm 1 - 3 mg FPFS-1169 | Arm 2 - 4.5 mg FPFS-1169 | Arm 3 - 6.0 mg FPFS-1169 |
|---|---|---|---|
| Started | 2 | 2 | 5 |
| Completed | 2 | 2 | 5 |

| Number of subjects in period 1 | Arm 4 - 7.5 mg FPFS-1169 | Arm 5 - 9.0 mg FPFS-1169 | Arm 6 - 12.0 mg FPFS-1169 |
|---|---|---|---|
| Started | 2 | 3 | 8 |
| Completed | 2 | 3 | 8 |

| Number of subjects in period 1 | Arm 7- 15.0 mg FPFS-1169 | Arm 8 - 18.0 mg FPFS-1169 | Arm 9 - 21.0 mg FPFS-1169 |
|---|---|---|---|
| Started | 2 | 3 | 1 |
| Completed | 2 | 3 | 1 |

| Number of subjects in period 1 | Arm 10 - 24.0 mg FPFS-1169 |
|---|---|
| Started | 1 |
| Completed | 1 |

## Baseline characteristics

### Reporting groups

| Reporting group title | Overall Trial Period |
|---|---|

Reporting group description: -

| Reporting group values | Overall Trial Period | Total | |
|---|---|---|---|
| Number of subjects | 10 | 10 | |
| Age categorical<br>Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 4 | 4 | |
| From 65-84 years | 6 | 6 | |
| 85 years and over | 0 | 0 | |
| Age continuous<br>Units: years | | | |
| arithmetic mean | 65.9 | | |
| standard deviation | ± 7.9 | - | |
| Gender categorical<br>Units: Subjects | | | |
| Female | 1 | 1 | |
| Male | 9 | 9 | |
| Height<br>Units: metre | | | |
| arithmetic mean | 1.74 | | |
| standard deviation | ± 0.06 | - | |
| Weight<br>Units: kilogram(s) | | | |
| arithmetic mean | 80.6 | | |
| standard deviation | ± 10.5 | - | |
| Body Mass Index (BMI)<br>Units: kilogram(s)/square metre | | | |
| arithmetic mean | 26.7 | | |
| standard deviation | ± 2.8 | - | |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | Arm 1 - 3 mg FPFS-1169 |
| Reporting group description: | |
| This was the lowest dose level evaluated in the study. 2 participants were administered 3.0 mg of FPFS-1169 as a subcutaneous injection. | |
| Reporting group title | Arm 2 - 4.5 mg FPFS-1169 |
| Reporting group description: | |
| This was the second dose level evaluated in the study. 2 participants were administered 4.5 mg of FPFS-1169 as a subcutaneous injection. | |
| Reporting group title | Arm 3 - 6.0 mg FPFS-1169 |
| Reporting group description: | |
| This was the third dose level evaluated in the study. 5 participants were administered 6.0 mg of FPFS-1169 as a subcutaneous injection. | |
| Reporting group title | Arm 4 - 7.5 mg FPFS-1169 |
| Reporting group description: | |
| This was the fourth dose level evaluated in the study. 2 participants were administered 7.5 mg of FPFS-1169 as a subcutaneous injection. | |
| Reporting group title | Arm 5 - 9.0 mg FPFS-1169 |
| Reporting group description: | |
| This was the fifth dose level evaluated in the study. 3 participants were administered 9.0 mg of FPFS-1169 as a subcutaneous injection. | |
| Reporting group title | Arm 6 - 12.0 mg FPFS-1169 |
| Reporting group description: | |
| This was the sixth dose level evaluated in the study. 8 participants were administered 12.0 mg of FPFS-1169 as a subcutaneous injection. | |
| Reporting group title | Arm 7- 15.0 mg FPFS-1169 |
| Reporting group description: | |
| This was the seventh dose level evaluated in the study. 2 participants were administered 15.0 mg of FPFS-1169 as a subcutaneous injection. | |
| Reporting group title | Arm 8 - 18.0 mg FPFS-1169 |
| Reporting group description: | |
| This was the eighth dose level evaluated in the study. 3 participants were administered 18.0 mg of FPFS-1169 as a subcutaneous injection. | |
| Reporting group title | Arm 9 - 21.0 mg FPFS-1169 |
| Reporting group description: | |
| This was the ninth dose level evaluated in the study. 1 participant was administered 21.0 mg of FPFS-1169 as a subcutaneous injection. | |
| Reporting group title | Arm 10 - 24.0 mg FPFS-1169 |
| Reporting group description: | |
| This was the highest dose level evaluated in the study. 1 participant was administered 24.0 mg of FPFS-1169 as a subcutaneous injection. | |
| Subject analysis set title | Subject 001 MED |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| This subject analysis set corresponds to the individual subject analysis for assessment of minimum effective dose (MED). | |
| Subject analysis set title | Subject 002 MED |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| This subject analysis set corresponds to the individual subject analysis for assessment of minimum effective dose (MED). | |
| Subject analysis set title | Subject 003 MED |

| | |
|---|---|
| Subject analysis set type | Full analysis |

Subject analysis set description:

This subject analysis set corresponds to the individual subject analysis for assessment of minimum effective dose (MED).

| | |
|---|---|
| Subject analysis set title | Subject 006 MED |
| Subject analysis set type | Full analysis |

Subject analysis set description:

This subject analysis set corresponds to the individual subject analysis for assessment of minimum effective dose (MED).

| | |
|---|---|
| Subject analysis set title | Subject 007 MED |
| Subject analysis set type | Full analysis |

Subject analysis set description:

This subject analysis set corresponds to the individual subject analysis for assessment of minimum effective dose (MED).

| | |
|---|---|
| Subject analysis set title | Subject 008 MED |
| Subject analysis set type | Full analysis |

Subject analysis set description:

This subject analysis set corresponds to the individual subject analysis for assessment of minimum effective dose (MED).

| | |
|---|---|
| Subject analysis set title | Subject 009 MED |
| Subject analysis set type | Full analysis |

Subject analysis set description:

This subject analysis set corresponds to the individual subject analysis for assessment of minimum effective dose (MED).

| | |
|---|---|
| Subject analysis set title | Subject 010 MED |
| Subject analysis set type | Full analysis |

Subject analysis set description:

This subject analysis set corresponds to the individual subject analysis for assessment of minimum effective dose (MED).

## Primary: Maximum Concentration (Cmax)

| | |
|---|---|
| End point title | Maximum Concentration (Cmax)[1] |

End point description:

| | |
|---|---|
| End point type | Primary |

End point timeframe:

Time points for pharmacokinetic evaluation of Cmax in plasma were as follows: pre-dose, 0.5, 1, 2, 4 and 6 hours post dose on Days 8, 15, 22 & 29.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Maximum Concentration (Cmax) were listed as descriptive statistics with no statistical analyses conducted.

| End point values | Arm 1 - 3 mg FPFS-1169 | Arm 2 - 4.5 mg FPFS-1169 | Arm 3 - 6.0 mg FPFS-1169 | Arm 4 - 7.5 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 5 | 2 |
| Units: ng/mL | | | | |
| arithmetic mean (full range (min-max)) | 1.937 (1.139 to 2.734) | 2.080 (1.435 to 2.725) | 3.934 (2.329 to 6.594) | 3.901 (2.800 to 5.002) |

| End point values | Arm 5 - 9.0 mg FPFS-1169 | Arm 6 - 12.0 mg FPFS-1169 | Arm 7- 15.0 mg FPFS-1169 | Arm 8 - 18.0 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 8 | 2 | 3 |
| Units: ng/mL | | | | |
| arithmetic mean (full range (min-max)) | 6.270 (2.784 to 9.483) | 9.213 (4.221 to 15.882) | 6.206 (5.580 to 6.831) | 7.849 (6.056 to 10.499) |

| End point values | Arm 9 - 21.0 mg FPFS-1169 | Arm 10 - 24.0 mg FPFS-1169 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1 | 1 | | |
| Units: ng/mL | | | | |
| arithmetic mean (full range (min-max)) | 16.653 (16.653 to 16.653) | 22.846 (22.846 to 22.846) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Time to maximum observed concentration (Tmax)

| End point title | Time to maximum observed concentration (Tmax)[2] |
|---|---|

End point description:

| End point type | Primary |
|---|---|

End point timeframe:

Time points for pharmacokinetic evaluation of Tmax in plasma were as follows: pre-dose, 0.5, 1, 2, 4 and 6 hours post dose on Days 8, 15, 22 & 29.

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Time to maximum observed concentration (Tmax) were listed as descriptive statistics with no statistical analyses conducted.

| End point values | Arm 1 - 3 mg FPFS-1169 | Arm 2 - 4.5 mg FPFS-1169 | Arm 3 - 6.0 mg FPFS-1169 | Arm 4 - 7.5 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 5 | 2 |
| Units: hour | | | | |
| median (full range (min-max)) | 0.50 (0.50 to 0.50) | 0.75 (0.50 to 1.00) | 0.50 (0.50 to 1.00) | 1.25 (0.50 to 2.00) |

| End point values | Arm 5 - 9.0 mg FPFS-1169 | Arm 6 - 12.0 mg FPFS-1169 | Arm 7- 15.0 mg FPFS-1169 | Arm 8 - 18.0 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 8 | 2 | 3 |
| Units: hour | | | | |

| | | | | |
|---|---|---|---|---|
| median (full range (min-max)) | 0.50 (0.50 to 2.00) | 0.50 (0.50 to 1.00) | 0.75 (0.50 to 1.00) | 2.00 (0.50 to 4.00) |

| **End point values** | Arm 9 - 21.0 mg FPFS-1169 | Arm 10 - 24.0 mg FPFS-1169 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1 | 1 | | |
| Units: hour | | | | |
| median (full range (min-max)) | 1.00 (1.00 to 1.00) | 0.50 (0.50 to 0.50) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Area under the curve from the time of dosing to the time of the last measurable concentration (AUC0-t)

| End point title | Area under the curve from the time of dosing to the time of the last measurable concentration (AUC0-t)[3] |
|---|---|

End point description:

| End point type | Primary |
|---|---|

End point timeframe:

Time points for pharmacokinetic evaluation of AUC0-t in plasma were as follows: pre-dose, 0.5, 1, 2, 4 and 6 hours post dose on Days 8, 15, 22 & 29.

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Area under the curve from the time of dosing to the time of the last measurable concentration (AUC0-t) were listed as descriptive statistics with no statistical analyses conducted.

| **End point values** | Arm 1 - 3 mg FPFS-1169 | Arm 2 - 4.5 mg FPFS-1169 | Arm 3 - 6.0 mg FPFS-1169 | Arm 4 - 7.5 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 5 | 2 |
| Units: ng/ml/h | | | | |
| arithmetic mean (full range (min-max)) | 5.872 (4.422 to 7.321) | 6.342 (5.512 to 7.172) | 14.003 (7.549 to 21.016) | 16.403 (13.724 to 19.083) |

| **End point values** | Arm 5 - 9.0 mg FPFS-1169 | Arm 6 - 12.0 mg FPFS-1169 | Arm 7- 15.0 mg FPFS-1169 | Arm 8 - 18.0 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 8 | 2 | 3 |
| Units: ng/ml/h | | | | |
| arithmetic mean (full range (min-max)) | 22.615 (14.260 to 37.500) | 25.392 (14.085 to 33.734) | 30.872 (28.936 to 32.808) | 36.320 (28.768 to 47.607) |

| End point values | Arm 9 - 21.0 mg FPFS-1169 | Arm 10 - 24.0 mg FPFS-1169 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1 | 1 | | |
| Units: ng/ml/h | | | | |
| arithmetic mean (full range (min-max)) | 70.610 (70.610 to 70.610) | 73.802 (73.802 to 73.802) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Minimum Effective Dose

| End point title | Minimum Effective Dose[4] |
|---|---|

End point description:

| End point type | Primary |
|---|---|

End point timeframe:

Assessment of Minimum Effective Dose was carried out from Day 1 through to Day 29.

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Minimum Effective Dose were listed as descriptive statistics with no statistical analyses conducted.

| End point values | Subject 001 MED | Subject 002 MED | Subject 003 MED | Subject 006 MED |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 1 | 1 | 1 | 1 |
| Units: milligram(s) | | | | |
| number (not applicable) | 12 | 6 | 7.5 | 15 |

| End point values | Subject 007 MED | Subject 008 MED | Subject 009 MED | Subject 010 MED |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 1 | 1 | 1 | 1 |
| Units: milligram(s) | | | | |
| number (not applicable) | 18 | 24 | 4.5 | 9 |

## Statistical analyses

No statistical analyses for this end point

## Primary: Maximum Concentration (Cmax) - Minimum Effective Dose

| End point title | Maximum Concentration (Cmax) - Minimum Effective Dose[5] |
|---|---|

End point description:

| End point type | Primary |
|---|---|

End point timeframe:

Time points for pharmacokinetic evaluation of Cmax in plasma were as follows: pre-dose, 0.5, 1, 2, 4 and 6 hours post dose on Days 8, 15, 22 & 29.

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Maximum Concentration (Cmax) - Minimum Effective Dose were listed as descriptive statistics with no statistical analyses conducted.

| End point values | Subject 001 MED | Subject 002 MED | Subject 003 MED | Subject 006 MED |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 1 | 1 | 1 | 1 |
| Units: ng/mL | | | | |
| number (not applicable) | 12.836 | 5.827 | 5.002 | 5.580 |

| End point values | Subject 007 MED | Subject 008 MED | Subject 009 MED | Subject 010 MED |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 1 | 1 | 1 | 1 |
| Units: ng/mL | | | | |
| number (not applicable) | 6.056 | 22.846 | 1.435 | 2.784 |

### Statistical analyses

No statistical analyses for this end point

## Primary: Area under the curve from the time of dosing to the time of the last measurable concentration (AUC0-t) - Minimum Effective Dose

| End point title | Area under the curve from the time of dosing to the time of the last measurable concentration (AUC0-t) - Minimum Effective Dose[6] |
|---|---|

End point description:

| End point type | Primary |
|---|---|

End point timeframe:

Time points for pharmacokinetic evaluation of AUC0-t in plasma were as follows: pre-dose, 0.5, 1, 2, 4 and 6 hours post dose on Days 8, 15, 22 & 29.

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Area under the curve from the time of dosing to the time of the last measurable concentration (AUC0-t) - Minimum Effective Dose were listed as descriptive statistics with no statistical

analyses conducted.

| End point values | Subject 001 MED | Subject 002 MED | Subject 003 MED | Subject 006 MED |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 1 | 1 | 1 | 1 |
| Units: ng/mL/h | | | | |
| number (not applicable) | 33.734 | 18.030 | 19.083 | 28.936 |

| End point values | Subject 007 MED | Subject 008 MED | Subject 009 MED | Subject 010 MED |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 1 | 1 | 1 | 1 |
| Units: ng/mL/h | | | | |
| number (not applicable) | 32.586 | 73.802 | 5.512 | 14.260 |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum Mean Change from Baseline (UPDRS Part III) - Minimum Effective Dose

| End point title | Maximum Mean Change from Baseline (UPDRS Part III) - Minimum Effective Dose |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

Evaluation of UPDRS and changes from baseline were assessed at set timepoints from Day 1 through to the end of study.

| End point values | Subject 001 MED | Subject 002 MED | Subject 003 MED | Subject 006 MED |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 1 | 1 | 1 | 1 |
| Units: UPDRS Score | | | | |
| number (not applicable) | -8.0 | -3.0 | -2.0 | -4.0 |

| End point values | Subject 007 MED | Subject 008 MED | Subject 009 MED | Subject 010 MED |
|---|---|---|---|---|

| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
|---|---|---|---|---|
| Number of subjects analysed | 1 | 1 | 1 | 1 |
| Units: UPDRS Score | | | | |
| number (not applicable) | -8.0 | -2.0 | -6.0 | -7.0 |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum Improvement in Timed Walk Test

| End point title | Maximum Improvement in Timed Walk Test |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

Evaluation of improvement in timed walk test were assessed at set timepoints from Day 1 through to the end of study.

| End point values | Arm 1 - 3 mg FPFS-1169 | Arm 2 - 4.5 mg FPFS-1169 | Arm 3 - 6.0 mg FPFS-1169 | Arm 4 - 7.5 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 5 | 2 |
| Units: second | | | | |
| number (not applicable) | 0.1 | 0.7 | 0.6 | 1.4 |

| End point values | Arm 5 - 9.0 mg FPFS-1169 | Arm 6 - 12.0 mg FPFS-1169 | Arm 7- 15.0 mg FPFS-1169 | Arm 8 - 18.0 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 8 | 2 | 3 |
| Units: second | | | | |
| number (not applicable) | 1.4 | 0.88 | 0.65 | 0.47 |

| End point values | Arm 9 - 21.0 mg FPFS-1169 | Arm 10 - 24.0 mg FPFS-1169 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1 | 1 | | |
| Units: second | | | | |
| number (not applicable) | 0.2 | 0.7 | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time of Maximum Improvement - Timed Walk Test

| End point title | Time of Maximum Improvement - Timed Walk Test |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

Evaluation of improvement in timed walk test were assessed at set timepoints from Day 1 through to the end of study.

| End point values | Arm 1 - 3 mg FPFS-1169 | Arm 2 - 4.5 mg FPFS-1169 | Arm 3 - 6.0 mg FPFS-1169 | Arm 4 - 7.5 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 5 | 2 |
| Units: hour | | | | |
| number (not applicable) | 6.0 | 0.5 | 6.0 | 6.0 |

| End point values | Arm 5 - 9.0 mg FPFS-1169 | Arm 6 - 12.0 mg FPFS-1169 | Arm 7- 15.0 mg FPFS-1169 | Arm 8 - 18.0 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 8 | 2 | 3 |
| Units: hour | | | | |
| number (not applicable) | 1.0 | 5.0 | 2.0 | 3.0 |

| End point values | Arm 9 - 21.0 mg FPFS-1169 | Arm 10 - 24.0 mg FPFS-1169 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1 | 1 | | |
| Units: hour | | | | |
| number (not applicable) | 0.5 | 0.5 | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Treatment Emergent Adverse Events

| End point title | Treatment Emergent Adverse Events |
|---|---|

End point description:

This endpoint relates to the number of patients who reported a treatment emergent adverse event (TEAEs) during the study.

There were a total of 18 treatment emergent adverse events reported during the study. Of these, 16 were reported following administration of subcutaneous injections of FPFS-1169. Two adverse events were reported following the standard dose of levodopa/carbidopa on Study Day 1. One of the treatment emergent adverse events was considered to be moderate in severity. All other events were considered to be mild in severity.

| End point type | Secondary |
|---|---|

End point timeframe:

Collection of treatment emergent adverse events occurred from the point of dose administration until completion of the end of study.

| **End point values** | Arm 1 - 3 mg FPFS-1169 | Arm 2 - 4.5 mg FPFS-1169 | Arm 3 - 6.0 mg FPFS-1169 | Arm 4 - 7.5 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 5 | 2 |
| Units: Number of Subjects | 1 | 0 | 2 | 0 |

| **End point values** | Arm 5 - 9.0 mg FPFS-1169 | Arm 6 - 12.0 mg FPFS-1169 | Arm 7- 15.0 mg FPFS-1169 | Arm 8 - 18.0 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 8 | 2 | 3 |
| Units: Number of Subjects | 1 | 4 | 0 | 1 |

| **End point values** | Arm 9 - 21.0 mg FPFS-1169 | Arm 10 - 24.0 mg FPFS-1169 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1 | 1 | | |
| Units: Number of Subjects | 1 | 0 | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Laboratory Parameters

| End point title | Laboratory Parameters |
|---|---|

End point description:

This primary endpoint will report the number of subjects who had out of range results for any of the Laboratory Parameters (biochemistry, haematology & urinalysis).

This endpoint will only report number of subjects who had out of range results from Day 1 onwards following administration of the IMP until the completion of the post study visit.

There were no clinically significant biochemistry, haematology or urinalysis results during the study.

| End point type | Secondary |
|---|---|

End point timeframe:

Laboratory Parameters (biochemistry, haematology and urinalysis) were measured at set time points from Day 1 until the end of the study.

| End point values | Arm 1 - 3 mg FPFS-1169 | Arm 2 - 4.5 mg FPFS-1169 | Arm 3 - 6.0 mg FPFS-1169 | Arm 4 - 7.5 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 5 | 2 |
| Units: Number of Subjects | 2 | 2 | 5 | 2 |

| End point values | Arm 5 - 9.0 mg FPFS-1169 | Arm 6 - 12.0 mg FPFS-1169 | Arm 7- 15.0 mg FPFS-1169 | Arm 8 - 18.0 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 8 | 2 | 3 |
| Units: Number of Subjects | 3 | 8 | 2 | 3 |

| End point values | Arm 9 - 21.0 mg FPFS-1169 | Arm 10 - 24.0 mg FPFS-1169 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1 | 1 | | |
| Units: Number of Subjects | 1 | 1 | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Vital Signs Parameters

| End point title | Vital Signs Parameters |
|---|---|

End point description:

This primary endpoint will report the number of subjects who had out of range results for any of the Vital Sign Parameters (systolic and diastolic blood pressure, pulse, oral temperature & respiration rate).

This endpoint will only report number of subjects who had out of range results from Day 1 onwards following administration of the IMP until the completion of the post study visit.

There were no clinically significant changes in vital signs parameters during the study at any dose level evaluated.

| End point type | Secondary |
|---|---|

End point timeframe:

Vital Sign Parameters (systolic and diastolic blood pressure, pulse, respiration rate & oral temperature) were measured at set time points from Day 1 until the end of the study.

| End point values | Arm 1 - 3 mg FPFS-1169 | Arm 2 - 4.5 mg FPFS-1169 | Arm 3 - 6.0 mg FPFS-1169 | Arm 4 - 7.5 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 5 | 2 |
| Units: Number of Subjects | 2 | 2 | 5 | 2 |

| End point values | Arm 5 - 9.0 mg FPFS-1169 | Arm 6 - 12.0 mg FPFS-1169 | Arm 7- 15.0 mg FPFS-1169 | Arm 8 - 18.0 mg FPFS-1169 |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 8 | 2 | 3 |
| Units: Number of Subjects | 3 | 8 | 2 | 3 |

| End point values | Arm 9 - 21.0 mg FPFS-1169 | Arm 10 - 24.0 mg FPFS-1169 | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1 | 1 | | |
| Units: Number of Subjects | 1 | 1 | | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events were reported from the time of signing informed consent until completion of the end of the study.

| | |
|---|---|
| Assessment type | Non-systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 8.0 |

### Reporting groups

| | |
|---|---|
| Reporting group title | Arm 1 - 3 mg FPFS-1169 |

Reporting group description:

This was the lowest dose level evaluated in the study. 2 participants were administered 3.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Reporting group title | Arm 2 - 4.5 mg FPFS-1169 |

Reporting group description:

This was the second dose level evaluated in the study. 2 participants were administered 4.5 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Reporting group title | Arm 3 - 6.0 mg FPFS-1169 |

Reporting group description:

This was the third dose level evaluated in the study. 5 participants were administered 6.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Reporting group title | Arm 4 - 7.5 mg FPFS-1169 |

Reporting group description:

This was the fourth dose level evaluated in the study. 2 participants were administered 7.5 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Reporting group title | Arm 5 - 9.0 mg FPFS-1169 |

Reporting group description:

This was the fifth dose level evaluated in the study. 3 participants were administered 9.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Reporting group title | Arm 6 - 12.0 mg FPFS-1169 |

Reporting group description:

This was the sixth dose level evaluated in the study. 8 participants were administered 12.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Reporting group title | Arm 7- 15.0 mg FPFS-1169 |

Reporting group description:

This was the seventh dose level evaluated in the study. 2 participants were administered 15.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Reporting group title | Arm 8 - 18.0 mg FPFS-1169 |

Reporting group description:

This was the eighth dose level evaluated in the study. 3 participants were administered 18.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Reporting group title | Arm 9 - 21.0 mg FPFS-1169 |

Reporting group description:

This was the ninth dose level evaluated in the study. 1 participant was administered 21.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Reporting group title | Arm 10 - 24.0 mg FPFS-1169 |

Reporting group description:

This was the highest dose level evaluated in the study. 1 participant was administered 24.0 mg of FPFS-1169 as a subcutaneous injection.

| | |
|---|---|
| Reporting group title | Baseline Dosing - Levodopa/Carbadopa |

Reporting group description:

This reporting group corresponds to all patients who reported an adverse event following administration

| **Serious adverse events** | Arm 1 - 3 mg FPFS-1169 | Arm 2 - 4.5 mg FPFS-1169 | Arm 3 - 6.0 mg FPFS-1169 |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

| **Serious adverse events** | Arm 4 - 7.5 mg FPFS-1169 | Arm 5 - 9.0 mg FPFS-1169 | Arm 6 - 12.0 mg FPFS-1169 |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 0 / 8 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

| **Serious adverse events** | Arm 7- 15.0 mg FPFS-1169 | Arm 8 - 18.0 mg FPFS-1169 | Arm 9 - 21.0 mg FPFS-1169 |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

| **Serious adverse events** | Arm 10 - 24.0 mg FPFS-1169 | Baseline Dosing - Levodopa/Carbadopa | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 10 (0.00%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| **Non-serious adverse events** | Arm 1 - 3 mg FPFS-1169 | Arm 2 - 4.5 mg FPFS-1169 | Arm 3 - 6.0 mg FPFS-1169 |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 2 (0.00%) | 2 / 5 (40.00%) |

| | | | |
|---|---|---|---|
| Investigations | | | |
| Blood glucose abnormal | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatine increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Parosmia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Feeling abnormal | | | |
| subjects affected / exposed | 1 / 2 (50.00%) | 0 / 2 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 0 | 1 |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Dysuria | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Insomnia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 2 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue | | | |

| | | | |
|---|---|---|---|
| disorders<br>Groin pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 |
| Infections and infestations<br>Gastroenteritis<br>subjects affected / exposed<br>occurrences (all) | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 |
| Metabolism and nutrition disorders<br>Increased appetite<br>subjects affected / exposed<br>occurrences (all) | 0 / 2 (0.00%)<br>0 | 0 / 2 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 |

| **Non-serious adverse events** | Arm 4 - 7.5 mg FPFS-1169 | Arm 5 - 9.0 mg FPFS-1169 | Arm 6 - 12.0 mg FPFS-1169 |
|---|---|---|---|
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed | 0 / 2 (0.00%) | 1 / 3 (33.33%) | 4 / 8 (50.00%) |
| Investigations<br>Blood glucose abnormal<br>subjects affected / exposed<br>occurrences (all) | 0 / 2 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Blood urea increased<br>subjects affected / exposed<br>occurrences (all) | 0 / 2 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Blood creatine increased<br>subjects affected / exposed<br>occurrences (all) | 0 / 2 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Nervous system disorders<br>Dizziness<br>subjects affected / exposed<br>occurrences (all) | 0 / 2 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0 | 2 / 8 (25.00%)<br>2 |
| Parosmia<br>subjects affected / exposed<br>occurrences (all) | 0 / 2 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0 | 1 / 8 (12.50%)<br>1 |
| General disorders and administration site conditions<br>Feeling abnormal<br>subjects affected / exposed<br>occurrences (all) | 0 / 2 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0 | 0 / 8 (0.00%)<br>0 |
| Gastrointestinal disorders | | | |

| | | | |
|---|---|---|---|
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 1 / 8 (12.50%) |
| occurrences (all) | 0 | 0 | 1 |
| Renal and urinary disorders | | | |
| Dysuria | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 1 / 8 (12.50%) |
| occurrences (all) | 0 | 0 | 1 |
| Psychiatric disorders | | | |
| Insomnia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Groin pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 3 (33.33%) | 0 / 8 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Infections and infestations | | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Increased appetite | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 0 / 8 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| **Non-serious adverse events** | Arm 7- 15.0 mg FPFS-1169 | Arm 8 - 18.0 mg FPFS-1169 | Arm 9 - 21.0 mg FPFS-1169 |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 3 (33.33%) | 1 / 1 (100.00%) |
| Investigations | | | |
| Blood glucose abnormal | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|---|---|---|
| Blood creatine increased | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Parosmia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| General disorders and administration site conditions | | | |
| Feeling abnormal | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Dysuria | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Insomnia | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Musculoskeletal and connective tissue disorders | | | |
| Groin pain | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Gastroenteritis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 2 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Increased appetite | | | |
| subjects affected / exposed | 0 / 2 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| **Non-serious adverse events** | Arm 10 - 24.0 mg FPFS-1169 | Baseline Dosing - Levodopa/Carbadopa | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 2 / 10 (20.00%) | |
| Investigations | | | |
| Blood glucose abnormal | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 10 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Blood creatine increased | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 10 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 10 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Parosmia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 10 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| General disorders and administration site conditions | | | |
| Feeling abnormal | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 10 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 10 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|---|---|---|
| Rash | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 10 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Renal and urinary disorders | | | |
| Dysuria | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 10 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Psychiatric disorders | | | |
| Insomnia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 10 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Groin pain | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 10 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Infections and infestations | | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 10 (10.00%) | |
| occurrences (all) | 0 | 1 | |
| Metabolism and nutrition disorders | | | |
| Increased appetite | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 10 (0.00%) | |
| occurrences (all) | 0 | 0 | |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 25 May 2006 | Protocol Amendment No. 1 (dated 25 May 2006) was generated to document the change to the Research Site used for the study. This was due to the superior facilities available at the purpose built Clinical Research Facility.<br><br>This amendment also documented additions to the list of co-investigators, inclusion of a follow-up telephone call for the purposes of monitoring the safety and well-being of the subjects, removal of pharmacokinetic samples and local tolerability assessments on Study Day 1 (standard levodopa/carbidopa dose) & correction of other minor typographical errors. |
| 28 February 2007 | Protocol Amendment No. 2 (dated 28 Feb 2007) documented the addition of a further Investigator. |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

N/A

Notes: